

Missense variants in *DPYSL5* cause a neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities

Médéric Jeanne,^{1,2} Hélène Demory,^{1,27} Aubin Moutal,^{3,27} Marie-Laure Vuillaume,^{1,2} Sophie Blesson,² Rose-Anne Thépault,¹ Sylviane Marouillat,¹ Judith Halewa,¹ Saskia M. Maas,⁴ M. Mahdi Motazacker,⁵ Grazia M.S. Mancini,⁶ Marjon A. van Slegtenhorst,⁶ Avgi Andreou,^{7,8} Helene Cox,^{7,8} Julie Vogt,^{7,8} Jason Laufman,⁹ Natella Kostandyan,¹⁰ Davit Babikyan,¹⁰ Miroslava Hancarova,¹¹ Sarka Bendova,¹¹ Zdenek Sedlacek,¹¹ Kimberly A. Aldinger,¹² Elliott H. Sherr,¹³ Emanuela Argilli,¹³ Eleina M. England,¹⁴ Séverine Audebert-Bellanger,¹⁵ Dominique Bonneau,¹⁶ Estelle Colin,¹⁶ Anne-Sophie Denommé-Pichon,¹⁷ Brigitte Gilbert-Dussardier,^{18,19} Bertrand Isidor,^{20,21} Sébastien Küry,^{20,21} Sylvie Odent,^{22,23} Richard Redon,²¹ Rajesh Khanna,³ William B. Dobyns,^{12,24} Stéphane Bézieau,^{20,21} Jérôme Honnorat,²⁵ Bernhard Lohkamp,²⁶ Annick Toutain,^{1,2} Frédéric Laumonnier^{1,2,*}

¹ UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France

² Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France

³ Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA

⁴ Amsterdam UMC, University of Amsterdam, Department of Clinical Genetics, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands

⁵ Department of Clinical Genetics, Laboratory of Genome Diagnostics, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands

⁶ Department of Clinical Genetics, Erasmus MC University Medical Center, 30125 CN Rotterdam, The Netherlands

⁷ West Midlands Regional Clinical Genetics Service, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham, BT15 2TG, UK

⁸ Birmingham Health Partners, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham, BT15 2TG, UK

⁹ Department of Clinical Genetics, Akron Children's Hospital, Akron, OH 44308-1062, USA

¹⁰ Department of Medical Genetics, Yerevan State Medical University after Mkhitar Heratsi, and Center of Medical Genetics and Primary Health Care, Yerevan 0001, Armenia

¹¹ Department of Biology and Medical Genetics, Charles University 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague 15006, Czech Republic

¹² Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA

¹³ Departments of Neurology and Pediatrics, Weill Institute of Neuroscience and Institute of Human Genetics, University of California, San Francisco, CA 94158, USA

- ¹⁴ Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- ¹⁵ Service de Génétique médicale et de biologie de la reproduction, Centre Hospitalier Régional Universitaire, 29200 Brest, France
- ¹⁶ Department of Biochemistry and Genetics, Angers University Hospital and UMR CNRS 6015-INSERM 1083, University of Angers, 49933 Angers France
- ¹⁷ Centre Hospitalier Universitaire de Dijon, UMR Inserm 1231, Team Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, 21070 Dijon, France
- ¹⁸ Service de Génétique, Centre Hospitalier Universitaire, 86021 Poitiers, France
- ¹⁹ Equipe d'Accueil 3808, Université de Poitiers, 86034 Poitiers, France
- ²⁰ Service de Génétique Médicale, Centre Hospitalier Universitaire, 44093 Nantes, France
- ²¹ Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du thorax, 44007 Nantes, France
- ²² Service de Génétique Clinique, Centre Référence Déficiences Intellectuelles de Causes Rares, Centre de Référence Anomalies du Développement, Centre Labellisé pour les Anomalies du Développement (CLAD) Ouest, Centre Hospitalier Universitaire de Rennes, 35203 Rennes, France
- ²³ Institut de Génétique et Développement de Rennes, CNRS, UMR 6290, Université de Rennes, 35043 Rennes, France
- ²⁴ Department of Pediatrics, University of Washington, Seattle, WA 98015, USA
- ²⁵ French Reference Center on autoimmune encephalitis, Hospices Civils de Lyon, Institut NeuroMyoGene, Inserm U1217/CNRS UMR 5310, Université de Lyon, Université Claude Bernard Lyon 1, 69008 Lyon, France
- ²⁶ Division of Molecular Structural Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17177 Stockholm, Sweden
- ²⁷ These authors contributed equally: Hélène Demory, Aubin Moutal

*** Correspondence: Frédéric LAUMONNIER, PhD**

UMR1253, iBrain, Team Neurogenomics and Neuronal Pathophysiology

Faculty of Medicine; 10 Bd Tonnellé; 37032 Tours cedex; France

Email: frederic.laumonnier@inserm.fr

Phone : +33 (0)2 47 36 60 62

Abstract

The Collapsin Response Mediator Protein (CRMP) family proteins are intracellular mediators of neurotrophic factors regulating neurite structure/spine formation and are essential for dendrite patterning and directional axonal pathfinding during brain developmental processes. Among this family, CRMP5/DPYSL5 plays a significant role in neuronal migration, axonal guidance, dendrite outgrowth and synapse formation by interacting with microtubules.

Here we report the identification of missense mutations in *DPYSL5* in nine individuals with brain malformations including corpus callosum agenesis and/or posterior fossa abnormalities, associated with variable degrees of intellectual disability. A recurrent *de novo* p.(Glu41Lys) variant was found in eight unrelated patients, and a p.(Gly47Arg) variant was identified in one individual from the first family reported with Ritscher-Schinzel syndrome. Functional analyses of the two missense mutations revealed impaired dendritic outgrowth processes in young developing hippocampal primary neuronal cultures. We further demonstrated that these mutations, both located in a same loop on the surface of DPYSL5 monomers and oligomers, reduced the interaction of DPYSL5 with neuronal cytoskeleton-associated proteins MAP2 and β III-Tubulin. Our findings collectively indicate that the p.(Glu41Lys) and p.(Gly47Arg) variants impair DPYSL5 function on dendritic outgrowth regulation by preventing the formation of the ternary complex with MAP2 and β III-Tubulin, ultimately leading to abnormal brain development. This study adds *DPYSL5* to the list of genes implicated in brain malformation and in neurodevelopmental disorders.

Running title: *DPYSL5* mutations in ID and brain malformations

Keywords: neurodevelopmental disorder; *de novo* missense variants; brain malformation;

DPYSL5; dendrite branching; primary neuronal cultures

Text

Intellectual Disabilities (ID) define a group of frequently associated neurodevelopmental disorders (NDD), which affect at least 1% of the general population, and consequently represent a major public health issue.¹ NDD are characterized by compromised brain and cognitive functions and impaired social behaviors. With the recent development of next-generation DNA sequencing in the past decades, it has been well-established that more than 900 genetic factors are implicated.² The integration of molecular and neurobiological data as well as animal and neuronal models have highlighted the critical role of impairments targeting synapse structure and function, chromatin remodeling and the interplay between the mechanisms regulating gene expression and synaptic function.^{3,4} Brain malformations, such as agenesis of the corpus callosum (ACC) or cerebellar dysplasia are congenital abnormalities sometimes associated with NDD. In particular, ACC is present in around 1-3% of individuals with impaired neurodevelopment.^{5,6} The etiologies of ACC are diverse and there has been a growing list of genetic causes identified in the last years, with more than 25 genes involved in either isolated or syndromic forms of ACC.⁵ Indeed, whole-exome sequencing (WES) approaches allowed the identification of novel candidate genes and pathogenic variants leading to ACC through abnormal vascular development, Semaphorin-mediated axonal guidance, and neuronal migration and specification.^{7,8}

In the frame of our research program on the genetic causes of isolated or syndromic severe ID using trio-based WES (HUGODIMS), we initially identified a *de novo* heterozygous missense mutation in *DPYSL5* (*Dihydropyrimidinase Like 5*, [MIM: 608383], RefSeq accession number NM_020134.4) in a simplex male individual with severe ID and complete ACC. This mutation (Chr2(GRCh37):27121488 G>A, NM_020134: c.121G>A, p.(Glu41Lys)) located in the second

exon of *DPYSL5* leads to a non-conservative valine to lysine substitution at position 41 of *DPYSL5* (**Figure 1**). We subsequently collected seven other unrelated individuals carrying the same *de novo* heterozygous variant as well as one individual whose father was unavailable for genetic analysis (**Figure S1-S3**). In each participating center, written informed consent was obtained from the individual's parents or legal representatives before blood sampling. The study received approval from the relevant local ethical committees. Clinical information was obtained by review of medical records and examination of affected individuals. When available, the brain MRI scans were reviewed by an expert (W.B. Dobyns) and the majority of them included axial, coronal and sagittal T1 and T2 sequences at a minimum. Routine clinical genetic and metabolic screenings performed during initial workup were negative in each case, which warranted further investigation on a research basis. All these individuals had severely delayed development with hypotonia (8/8), severe ID (7/7), often with absent speech (6/8) and behavioral problems, mainly aggressiveness (5/7). In addition, all individuals had neurological problems consisting of abnormal movements (5/8), ataxia (3/6), strabismus (5/8), and seizures were observed in 3 persons. Head circumference was below the normal range in 3 individuals (around -3 SD). ACC was observed in all individuals and associated with anomalies of the posterior fossa, consisting mostly of cerebellar hypoplasia (6/7) or Dandy-Walker malformation with encephalocele (1/7). When a careful review of the MRI was possible, hippocampal dysplasia was also noticed in 3 individuals (**Figure 1, Figure S4**). No consistent dysmorphic features seem to be recognizable in this series of individuals (**Table 1 and Supplemental Note**).

Additionally, we found a heterozygous missense variant (Chr2(GRCh37):27121506 G>A, NM_020134: c.139G>A, p.(Gly47Arg)) in the family from the original description of the Ritscher-Schinzel syndrome (RSS [MIM: 220210]) which includes two affected sisters (**Figure**

1, Table 1).^{8,9} One individual was deceased and no genetic material was available for testing.

The variant occurred *de novo* in the other affected sister as it was not detected in the parental DNAs, suggesting a likely gonadal mosaicism. Such inheritance mechanism has been previously proposed for other families with RSS.¹⁰ These two sisters, born to unrelated parents, both presented posterior fossa abnormalities (consisting of Dandy-Walker malformation in one), an atrioventricular canal, and craniofacial dysmorphic features with a large bulging skull.

Both p.(Glu41Lys) and p.(Gly47Arg) variants were absent in the control population database Genome Aggregation Databases (GnomAD v2.1.1, v3.1),¹¹ and were predicted to be pathogenic by several *in silico* prediction programs (**Table 2**). Gene constraint metrics (GnomAD v2.1.1, 141456 samples) indicate that *DPYSL5* is intolerant to both protein-truncating variation (pLI=1) and missense variation (missense Z score =3.08). Four nonsense or frameshift variants are described in the “non-neuro” v.2.1.1 and v.3.1 GnomAD datasets.

DPYSL5 is strongly expressed in the developing brain and encodes a protein, initially described as an antigen in autoimmune neurological syndromes, belonging to the Collapsin Response Mediator Proteins (CRMPs) family.¹²⁻¹⁴ These proteins are involved in the regulation of neuronal migration, axonal guidance, dendritic outgrowth, and synapse formation and plasticity during brain development.¹⁴⁻¹⁶ *DPYSL5* (or CRMP5) is a cytosolic protein (RefSeq accession number NP_064519.2) relaying semaphorin3A signaling, one of the molecular cues conducting axon and dendrite growth and guidance.^{16,17} In adults, *DPYSL5* is particularly detected in the midbrain, spinal cord, dorsal root ganglia, Purkinje cells and in neurogenesis areas of the brain.^{17,18} *DPYSL5* was also identified as a component of the postsynaptic density proteome,¹⁹ and it was recently described to modulate the surface trafficking and endocytosis

of the AMPA receptor subunit GluA2 via the phosphorylation of GluA2 at Serine 880, suggesting a specific function at the glutamatergic synapse.²⁰

DPYSL5 can form homo- as well as hetero-tetramers with DPYSL2, 3 and 4 to participate in signal transduction, cytoskeleton rearrangements, and endocytosis.²¹ Protein structural modeling analyses using the crystal structure of human DPYSL5 indicated that glutamate 41 and glycine 47 are both located in the same loop on the surface of DPYSL5 monomers and oligomers (**Figure 1C**). No significant difference in calculated free energy (ΔG) between the wildtype (WT) and variant forms of DPYSL5 was found. The loop is a part of the β -sandwich domain and is not involved in interactions between the subunits of the DPYSL5 tetramer (**Figure 1C,D**). The modeled structures are very similar to the WT protein with minimal differences observed in the loop region (**Figure 1D**). Based on this, the p.(Glu41Lys) and p.(Gly47Arg) variants are unlikely to affect either protein stability or oligomeric assembly. However, both variants will alter potential interaction areas of DPYSL5 with other proteins in various ways. The p.(Glu41Lys) variant changes the charge and hence the electrostatic surface so that potential interaction may not be possible anymore. The p.(Gly47Arg) again introduces a positive charge thus altering the surface potential. Additionally, the flexibility of the loop will be restricted and a larger side chain is introduced giving potentially steric problems for interactions as well.

Accumulating evidence indicates that DPYSL5 is an inhibitory regulator of both neurite outgrowth and axonal guidance contributing to neuronal polarity, as well as dendrite development at early developmental stages.^{17,22,23} We thus evaluated the impact of both p.(Glu41Lys) and p.(Gly47Arg) variants on axonal and dendritic outgrowth of young developing hippocampal primary neuronal cultures transfected (day *in vitro* 4) with plasmids

containing EGFP-DPYSL5 wild type (WT) or variant forms (**Figure 2A**). We used a pEGFP-C1 plasmid construct containing the full-length human *DPYSL5* cDNA, allowing the production of GFP-DPYSL5 WT fusion proteins.²² The candidate mutations were then generated by using site-directed mutagenesis (see **supplemental methods**). All constructs were initially tested in HEK293T cells and displayed similar DPYSL5 protein levels, indicating that both mutant proteins are stable as expected from the structural calculations (**Figure S5**). When DPYSL5 WT and variants were transfected in primary neuronal cultures, the total axonal length per neuron was similar between GFP (control), EGFP-DPYSL5 WT, and EGFP-DPYSL5 Glu41Lys or Gly47Arg conditions (**Figure 2B**). As reported before,²² the total dendritic length was decreased in EGFP-DPYSL5-WT neurons (**Figure 2B**). However, both DPYSL5 mutant proteins abolished this inhibitory function on dendrite outgrowth, suggesting a loss of function mechanism (**Figure 2B**). Although the p.(Glu41Lys) and p.(Gly47Arg) variants are not likely to affect either protein stability or oligomeric assembly, they could alter the interaction of DPYSL5 with other proteins. Both variants add an exposed positive charge to the electrostatic surface of the protein which may result in disruption of protein-protein interactions.

To elicit its inhibitory function on neurite outgrowth, DPYSL5 counteracts DPYSL2 by creating a ternary complex with MAP2 and β III-Tubulin, and increased levels of DPYSL5 in primary neuronal cultures transfected with GFP-DPYSL5 inhibit tubulin polymerization and neurite outgrowth.^{22,23} We hypothesized that the loss of the inhibitory function of DPYSL5 in neurite outgrowth was related to deficient binding to MAP2 and β III-Tubulin. We transfected the DPYSL5 variants in a catecholamine A differentiated (CAD) neuronal cell line prior to performing co-immunoprecipitation (**Figure 3A**). We found that both variants reduced DPYSL5 binding to MAP2 and β III-Tubulin (**Figure 3B**), and the p.(Gly47Arg) substitution increased

DPYSL5 binding to DPYSL2. These results suggest that the p.(Glu41Lys) and p.(Gly47Arg) variants impair DPYSL5 function by preventing the formation of the ternary complex with MAP2 and β III-Tubulin. This would allow DPYSL2 to keep promoting neurite outgrowth because of loss of inhibition by DPYSL5. Because the residues Glutamate 41 and Glycine 47 of DPYSL5 are not located at the direct interface between monomers of a putative DPYSL5/DPYSL2 heterotetramer, it is unclear how the p.(Gly47Arg) mutation impacts DPYSL5 interaction with DPYSL2 while p.(Glu41Lys) variant does not. Recent structural studies suggested that the C-terminal domain of DPYSL2 wraps around the next monomer to stabilize this protein complex.²⁴ We hypothesize that the p.(Gly47Arg) mutation may be located in the vicinity of one of the binding sites on the DPYSL5 monomer for binding to DPYSL2, although no 3D structure for the C-terminal domain of DPYSL2 is available to test this possibility.

In order to identify other *de novo* candidate mutations in *DPYSL5*, we analyzed the de novo-db database (current release v.1.6.1, March 2021 accessed) and we discovered two other missense variants, p.(Asp81Asn) and p.(Val364Ile), previously described in large cohorts of individuals with NDD, but detailed clinical phenotypes of these individuals are not available.^{25,26} However, the p.(Asp81Asn) variant has been detected in 10 and 13 individuals from the « non-neuro » GnomAD database and from the total datasets of GnomAD database respectively, thus questioning its deleterious impact. The variant c.1090G>A, p.(Val364Ile) is absent from GnomAD and dbSNP databases. It is predicted to be benign by SIFT and Polyphen-2 *in silico* tools whereas Mutation Taster indicates it would be disease causing. According to Splice site Finder-like, MaxEntScan and GeneSplicer programs, an impact of this variant on splicing could not be excluded. Protein structural modeling analyses revealed that the

modeled structure and free energy of the mutant protein is very similar to the WT protein (data not shown).

There is overwhelming evidence about the critical roles of the DPYSL/CRMPs in brain developmental processes such as axonal growth and guidance, dendrite branching, organization and plasticity, and synapse activity and maturation, through their interaction with different types of neuronal molecules (cytoskeleton-associated proteins, synaptic receptors, ion channels).^{16,27,28} Besides their developmental function (i.e. regulation of axonal growth), the DPYSL/CRMPs proteins have been also detected in synaptic fractions and might play a significant role in synaptic plasticity and activity.^{18,29,30}

Furthermore, multi-omics translational approaches indicated that CRMPs expression (RNA, protein) is altered in various human brain disorders including mental (schizophrenia, mood disorders) and neurological (Alzheimer's, prion encephalopathy, epilepsy) conditions.¹⁶ At the genetic level, several missense variants reported in denovo-db have been described in individuals with ASD for *DPYSL2* (p.(His438Asn), p.(Arg601Cys)) and *DPYSL3* (p.(Val139Ile), p.(Ser541Tyr)).^{26,31,32}

The study of homozygous *Dpyls5* knock-out mouse models (*Dpyls5*^{-/-}) revealed abnormal dendritic development of Purkinje cells during the period of dendritic branching, at postnatal day 21 (P21) and P28, but not at P14, and altered electrophysiological activity between parallel fibers and Purkinje cells in adult *Dpyls5*^{-/-} mice.¹⁸ Lastly, they display abnormal limb-clasping reflexes which are also consistent with abnormal central synaptic function.¹⁸ These data should however be considered carefully with regard to the missense p.(Glu41Lys) and p.(Gly47Arg) variants leading to a possible dominant-negative effect and a different pathophysiological outcome (i.e. brain neuroanatomical defects, ID) as no abnormalities in brain cyto-architecture were described in both heterozygous and full KO mouse models.¹⁸

Importantly, all individuals with the p.(Glu41Lys) variant had ACC - a feature which seems to be a hallmark of *DPYSL5* deleterious impact - associated, in cases where a careful examination of brain MRI was possible, with infratentorial anomalies such as hypoplasia of vermis and cerebellar hemispheres. Posterior fossa abnormalities are also cardinal features of the Ritscher-Schinzel syndrome suggesting that *DPYSL5* mutations may cause a spectrum of central nervous system defects, particularly as agenesis of the corpus callosum is not a feature of this condition. On the basis of the cardinal features described in the original family, and further clinical reports published in the following years, the name of Cranio-Cerebello-Cardiac or 3C syndrome was proposed, and additional signs were described. Currently, it is admitted that the clinical criteria of Ritscher-Schinzel syndrome are craniofacial features with a prominent occiput and/or forehead, cerebellar defects, generally associated with a variable degree of ID, congenital heart malformation, and in some cases cleft palate or ocular coloboma.³³ However, this condition is very heterogeneous both clinically and genetically.³⁴ Some cases were proven to be caused by chromosome anomalies such as 6p terminal microdeletion,¹⁰ and in the last years biallelic pathogenic variants have been reported in *WASHC5* in individuals of First Nations heritage from Canada,³⁵ hemizygous variants in *CCDC22*,³⁶ and more recently biallelic variants in *VPS35L*.³⁴ It is therefore important to note that a mutation in *DPYSL5* is the genetic cause of the condition observed in the original family, thus raising the question of the relevance of considering the Ritscher-Schinzel syndrome as a unique entity.

It is also interesting to note that the affected members from this family had a cardiac defect, but the role of *DPYSL5* in the developing heart is unknown. A recent study (BBI Allen single cell atlases), which reported single gene expression for several tissues during human fetal

development, indicated that *DPYSL5* is expressed at very low levels in the fetal heart (<11 TPM) in contrast to its high expression in brain (362 TPM) and cerebellum (287 TPM).³⁷ In the adult, *DPYSL5* is exclusively expressed in the brain, according to GTEx Portal data. We cannot either exclude the association of two different conditions in this family.

In conclusion, through a multi-center collaboration, we identified two pathogenic missense mutations in *DPYSL5*, including a recurrent *de novo* variant carried by 8 individuals. The variants cause a defective inhibitory regulation of neurite outgrowth and dendrite development, and they are responsible for a severe syndromic form of NDD/ID with brain malformations. This study highlights the importance of DPYSL/CRMPs in neuronal development and shows how alterations of their regulatory functions lead to brain dysfunction. The generation and analysis of neuronal (iPSC-derived neurons) and animal models expressing the p.(Glu41Lys) or p.(Gly47Arg) variants of *DPYSL5* will likely provide a detailed characterization of their pathophysiological consequences on brain developmental architecture.

Description of Supplemental Data

Supplemental Data include clinical details section, Materials and methods section, and 5 figures.

Competing Interests statement

The authors declare no competing interests

Acknowledgements

We thank the participants and families involved in the study. This work was funded by the Association pour le Développement de la Neurogénétique (to F.L.), the Programme Hospitalier de Recherche Clinique Inter-Régional (grant no. NCT02136849 to S.Bézieau), and the Czech Ministries of Health and Education (grants 17-29423A and LM2018132 to Z.S.). We also thank the « IBiSA Electron Microscopy Facility » of the University of Tours for management and access to the confocal microscopy platform, and the genomics and bioinformatics core facilities of Nantes (GenoBiRD, Biogenouest) for their support to sequencing and data analysis. Exome Sequencing and analysis provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) were funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between Wellcome and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051].

Web Resources

Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org/>

denovo-db, Seattle, WA, <https://denovo-db.gs.washington.edu>

GnomAD, <https://gnomad.broadinstitute.org>

GTEx Portal, <http://www.gtexportal.org/home/>

BBi Allen single cell atlases, <https://descartes.brotmanbaty.org/>

dbSNP, <https://www.ncbi.nlm.nih.gov/snp/>

ReqSeq accession number for *DPYSL5*, <https://www.ncbi.nlm.nih.gov/gene/56896>

Data and Code Availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. Zablotsky, B., Black, L.I., Maenner, M.J., Schieve, L.A., Danielson, M.L., Bitsko, R.H., Blumberg, S.J., Kogan, M.D., and Boyle, C.A. (2019). Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009-2017. *Pediatrics* 144, e20190811.
2. Chiurazzi, P., Kiani, A.K., Miertus, J., Paolacci, S., Barati, S., Manara, E., Stuppia, L., Gurrieri, F., and Bertelli, M. (2020). Genetic analysis of intellectual disability and autism. *Acta Biomed.* 91, e2020003.
3. Mossink, B., Negwer, M., Schubert, D., and Nadif Kasri, N. (2020). The emerging role of chromatin remodelers in neurodevelopmental disorders: a developmental perspective. *Cell Mol Life Sci.* doi: 10.1007/s00018-020-03714-5. Epub ahead of print.
4. Moyses-Oliveira, M., Yadav, R., Erdin, S., and Talkowski, M.E. (2020). New gene discoveries highlight functional convergence in autism and related neurodevelopmental disorders. *Curr. Opin. Genet. Dev.* 65, 195-206.
5. Hofman, J., Hutny, M., Sztuba, K., and Paprocka, J. (2020). Corpus Callosum Agenesis: An Insight into the Etiology and Spectrum of Symptoms. *Brain Sci.* 10, 625.
6. Duarte, K., Heide, S., Poëa-Guyon, S., Rousseau, V., Depienne, C., Rastetter, A., Nava, C., Attié-Bitach, T., Razavi, F., Martinovic, J., et al. (2020). PAK3 mutations responsible for severe intellectual disability and callosal agenesis inhibit cell migration. *Neurobiol. Dis.* 136, 104709.
7. Edwards, T.J., Sherr, E.H., Barkovich, A.J., and Richards, L.J. (2014). Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes. *Brain* 137, 1579-1613.
8. Aldinger, K.A., Timms, A.E., Thomson, Z., Mirzaa, G.M., Bennett, J.T., Rosenberg, A.B., Roco, C.M., Hirano, M., Abidi, F., Haldipur, P., et al. (2019). Redefining the Etiologic Landscape of Cerebellar Malformations. *Am. J. Hum. Genet.* 105, 606-615.
9. Ritscher, D., Schinzel, A., Boltshauser, E., Briner, J., Arbenz, U., and Sigg, P. (1987). Dandy-Walker(like) malformation, atrio-ventricular septal defect and a similar pattern of minor anomalies in 2 sisters: a new syndrome? *Am. J. Med. Genet.* 26, 481-491.

10. Descipio, C., Schneider, L., Young, T.L., Wasserman, N., Yaeger, D., Lu, F., Wheeler, P.G., Williams, M.S., Bason, L., Jukofsky, L., et al. (2005). Subtelomeric deletions of chromosome 6p: molecular and cytogenetic characterization of three new cases with phenotypic overlap with Ritscher-Schinzel (3C) syndrome. *Am. J. Med. Genet. A* 134A, 3-11.
11. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581, 434-443.
12. Fukada, M., Watakabe, I., Yuasa-Kawada, J., Kawachi, H., Kuroiwa, A., Matsuda, Y., and Noda, M. (2000). Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family. *J. Biol. Chem.* 275, 37957-3796.
13. Ricard, D., Rogemond, V., Charrier, E., Aguera, M., Bagnard, D., Belin, M.F., Thomasset, N., and Honnorat, J. (2001). Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/CRMP2 in Sema3a- sensitive oligodendrocytes. *J. Neurosci.* 21, 7203-7214.
14. Nakamura, F., Ohshima, T., and Goshima, Y. (2020). Collapsin Response Mediator Proteins: Their Biological Functions and Pathophysiology in Neuronal Development and Regeneration. *Front. Cell. Neurosci.* 14, 188.
15. Charrier, E., Reibel, S., Rogemond, V., Aguera, M., Thomasset, N., and Honnorat, J. (2003). Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. *Mol. Neurobiol.* 28, 51-64.
16. Quach, T.T., Honnorat, J., Kolattukudy, P.E., Khanna, R., and Duchemin, A.M. (2015). CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases. *Mol. Psychiatry* 20, 1037-1045.
17. Bretin, S., Reibel, S., Charrier, E., Maus-Moatti, M., Auvergnon, N., Thevenoux, A., Glowinski, J., Rogemond, V., Prémont, J., Honnorat, J., et al. (2005). Differential expression of CRMP1, CRMP2A, CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. *J. Comp. Neurol.* 486, 1-17.
18. Yamashita, N., Mosinger, B., Roy, A., Miyazaki, M., Ugajin, K., Nakamura, F., Sasaki, Y., Yamaguchi, K., Kolattukudy, P., and Goshima, Y. (2011). CRMP5 (collapsin response mediator protein 5) regulates dendritic development and synaptic plasticity in the cerebellar Purkinje cells. *J. Neurosci.* 31, 1773-1779.

19. Collins, M.O., Husi, H., Yu, L., Brandon, J.M., Anderson, C.N., Blackstock, W.P., Choudhary, J.S., and Grant, S.G. (2006). Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. *J. Neurochem.* *97 Suppl 1*, 16-23.
20. Lin, Y.S., Lin, Y.F., Chen, K.C., Yang, Y.K., and Hsiao, Y.H. (2019). Collapsin response mediator protein 5 (CRMP5) causes social deficits and accelerates memory loss in an animal model of Alzheimer's disease. *Neuropharmacology* *157*, 107673.
21. Ponnusamy, R., and Lohkamp, B. (2013). Insights into the oligomerization of CRMPs: crystal structure of human collapsin response mediator protein 5. *J. Neurochem.* *125*, 855-868.
22. Brot, S., Rogemond, V., Perrot, V., Chounlamountri, N., Auger, C., Honnorat, J., and Moradi-Améli, M. (2010). CRMP5 interacts with tubulin to inhibit neurite outgrowth, thereby modulating the function of CRMP2. *J. Neurosci.* *30*, 10639-10654.
23. Naudet, N., Moutal, A., Vu, H.N., Chounlamountri, N., Watrin, C., Cavagna, S., Malleval, C., Benetollo, C., Bardel, C., Dronne, M.A., et al. (2018). Transcriptional regulation of CRMP5 controls neurite outgrowth through Sox5. *Cell. Mol. Life Sci.* *75*, 67-79.
24. Niwa, S., Nakamura, F., Tomabechi, Y., Aoki, M., Shigematsu, H., Matsumoto, T., Yamagata, A., Fukai, S., Hirokawa, N., Goshima, Y., et al. (2017). Structural basis for CRMP2-induced axonal microtubule formation. *Sci Rep.* *7*, 10681.
25. Deciphering Developmental Disorders Study. (2017). Prevalence and architecture of de novo mutations in developmental disorders. *Nature* *542*, 433-438.
26. De Rubeis, S., He, X., Goldberg, A.P., Poultney, C.S., Samocha, K., Cicek, A.E., Kou, Y., Liu, L., Fromer, M., Walker, S., et al. (2014). Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* *515*, 209-215.
27. Nakamura, F., Ohshima, T., and Goshima, Y. (2020). Collapsin Response Mediator Proteins: Their Biological Functions and Pathophysiology in Neuronal Development and Regeneration. *Front. Cell. Neurosci.* *14*, 188.
28. Quach, T.T., Stratton, H.J., Khanna, R., Kolattukudy, P.E., Honnorat, J., Meyer, K., and Duchemin, A.M. (2020). Intellectual disability: dendritic anomalies and emerging genetic perspectives. *Acta Neuropathol.* doi: 10.1007/s00401-020-02244-5. Epub ahead of print.
29. Hou, S.T. (2020). The regulatory and enzymatic functions of CRMPs in neuritogenesis, synaptic plasticity, and gene transcription. *Neurochem. Int.* *139*, 104795.

30. Wang, Y., Brittain, J.M., Wilson, S.M., and Khanna, R. (2010). Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. *Commun. Integr. Biol.* 3, 172-175.
31. Iossifov, I., O'Roak, B.J., Sanders, S.J., Ronemus, M., Krumm, N., Levy, D., Stessman, H.A., Witherspoon, K.T., Vives, L., Patterson, K.E., et al. (2014). The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 515, 216-221.
32. Tsutiya, A., Nakano, Y., Hansen-Kiss, E., Kelly, B., Nishihara, M., Goshima, Y., Corsmeier, D., White, P., Herman, G.E., and Ohtani-Kaneko, R. (2017). Human CRMP4 mutation and disrupted *Crmp4* expression in mice are associated with ASD characteristics and sexual dimorphism. *Sci. Rep.* 7, 16812.
33. Elliott, A.M., and Chudley, A. (2020). Ritscher-Schinzel syndrome. In *GeneReviews*[®] [Internet], Adam MP, Ardinger HH, Pagon RA, et al., ed. (Seattle (WA): University of Washington, Seattle), pp. 1993-2020.
34. Kato, K., Oka, Y., Muramatsu, H., Vasilev, F.F., Otomo, T., Oishi, H., Kawano, Y., Kidokoro, H., Nakazawa, Y., Ogi, T., et al. (2020). Biallelic VPS35L pathogenic variants cause 3C/Ritscher-Schinzel-like syndrome through dysfunction of retriever complex. *J. Med. Genet.* 57, 245-253.
35. Elliott, A.M., Simard, L.R., Coghlan, G., Chudley, A.E., Chodirker, B.N., Greenberg, C.R., Burch, T., Ly, V., Hatch, G.M., and Zelinski, T. (2013). A novel mutation in KIAA0196: identification of a gene involved in Ritscher-Schinzel/3C syndrome in a First Nations cohort. *J. Med. Genet.* 50, 819-822.
36. Kolanczyk, M., Krawitz, P., Hecht, J., Hupalowska, A., Miaczynska, M., Marschner, K., Schlack, C., Emmerich, D., Kobus, K., Kornak, U., et al. (2015). Missense variant in *CCDC22* causes X-linked recessive intellectual disability with features of Ritscher-Schinzel/3C syndrome. *Eur. J. Hum. Genet.* 23, 633-638.
37. Cao, J., O'Day, D.R., Pliner, H.A., Kingsley, P.D., Deng, M., Daza, R.M., Zager, M.A., Aldinger, K.A., Blecher-Gonen, R., Zhang, F., et al. (2020). A human cell atlas of fetal gene expression. *Science* 370, eaba7721.

Figure legends

Figure 1: Neuro-anatomical and molecular analyses of *DPYSL5* mutations

A- Midsagittal brain MRIs of three individuals carrying a *de novo* p.(Glu41Lys) heterozygous variant of *DPYSL5* revealing complete agenesis of corpus callosum (ACC) and mild cerebellar hypoplasia (Individual 1), total ACC with normal cerebellum size but with mild mega cisterna magna (Individual 2), and total ACC and mild hypoplasia of the inferior cerebellar vermis (Individual 3); **B-** Schematic representation of *DPYSL5* transcript and protein and localization of the two mutations p.(Glu41Lys) (E41K) and p.(Gly47Arg) (G47R); **C-** Homo-tetramer model of human *DPYSL5*. The four subunits are shown in ribbon representation and colored differently (green, blue, brown and red). In one chain (blue) the location of the mutation sites is labeled and indicated by grey spheres; **D-** Close up view of the mutation site. Mutated residues are shown in stick representation. The crystal structure of human *DPYSL5* (4b91) is shown in blue. The modeled structures of E41K and G47R are shown in gold and coral, respectively.

Figure 2: Functional analyses of the impact of *DPYSL5* variants on neuronal development

A- Confocal microscopy images of neurons at 6 days of *in vitro* culture (D.I.V.) transfected at 2 D.I.V. with pEGFP (GFP), pEGFP-*DPYSL5* (WT), pEGFP-*DPYSL5* p.Glu41Lys (E41K) and pEGFP-*DPYSL5* p.Gly47Arg (G47R) and labeled with anti-Tau (axon) and anti-MAP2 (dendrites) antibodies. Scale bar, 50µm; **B-** Graphical representations of the axon and dendrite length measures in dot plots, each plot corresponding to one neuron for which the axonal length and the total dendritic length were measured. A one-way ANOVA parametric test with multiple comparisons (Tukey's Post hoc) was performed and found to be non-significant for the axon

length ($P=0.2272$; $F=1.488$; $R\text{-squared}=0.07148$), and significant for total dendritic length ($P=0.0003$; $F=7.377$; $R\text{-squared}=0.2762$). Three independent transfections including 15 neurons “pEGFP” (solid green circle), 15 neurons “EGFP-DPYSL5 WT” (pink diamond), 16 neurons “GFP-DPYSL5 E41K” (purple triangle) and 16 neurons “EGFP-DPYSL5 G47R” (red triangle). *, $P=0.0201$ (WT vs. G47R) or $P=0.0121$ (WT vs. E41K); ***, $P=0.0001$ (GFP vs. WT). Data are shown as mean $\pm$ SEM;

Figure 3. The p.(Glu41Lys) and p.(Gly47Arg) variants impair the physical interaction of DPYSL5 with the neuronal cytoskeleton-associated proteins MAP2 and tubulin β III.

A- Representative immunoblots showing GFP-DPYSL5 or GFP immunoprecipitation and co-immunoprecipitation of DPYSL5 associated proteins DPYSL2, endogenous DPYSL5 (indicated with an arrow), β III-tubulin and MAP2 from CAD cells transfected with the indicated DPYSL5 mutants or GFP as a negative control; **B-** Bar graph with scatter plots showing relative binding of the indicated proteins to GFP-DPYSL5. Both E41K and G47R mutations decreased binding to β III-tubulin and MAP2. DPYSL5-E41K showed decreased binding to endogenous DPYSL5 and DPYSL5-G47R had increased binding to DPYSL2 compared to wildtype (WT). *, $P<0.05$, Kruskal-Wallis test with Dunn’s post-hoc. Data are shown as mean $\pm$ SEM ($n=4$).

Table 1. Clinical findings of the individuals carrying missense mutations in *DPYSL5*

Individuals	1	2	3	4	5	6	7	8	9 (Ritscher-Schinzel)	10 Sister of 9
<i>DPYSL5</i> cDNA	c.121G>A	c.121G>A	c.121G>A	c.121G>A	c.121G>A	c.121G>A	c.121G>A	c.121G>A	c.139G>A	deceased
<i>DPYSL5</i> protein	p.Glu41Lys	p.Glu41Lys	p.Glu41Lys	p.Glu41Lys	p.Glu41Lys	p.Glu41Lys	p.Glu41Lys	p.Glu41Lys	p.Gly47Arg	(not tested)
Inheritance	htz, <i>de novo</i>	htz, <i>de novo</i>	htz, <i>de novo</i>	htz, <i>de novo</i>	htz, <i>de novo</i>	htz, <i>de novo</i>	htz, <i>de novo</i>	htz, <i>de novo</i>	htz, gonadal mosaicism suspected	N/A
Gender	M	M	M	F	F	F	F	F	F	F
Age on last examination	33 y	2.5 y	8.5 y	22 y	22 y	4.5 Y	17.5 y	5y	3.5 y	6 y
Prenatal findings	weak fetal movements	N/A	N/A	N/A	N/A	dilated ventricles at 36 weeks	weak fetal movements	None	N/A	N/A
Birth parameters										
Term (weeks)	38	42	42	40	39	39	39	40	37	37 + 4
Birth length / centile	50 cm / 67th	unknown	unknown	unknown	unknown	unknown	49 cm / 42th	53.3 cm / 90th	51 cm / 90th	48 cm / 50th
Birth weight / centile	3360 g / 68th	3040 g / 7th	4600 g / 97th	3800 / 75th-90th	3685 g / 75th	3969g / 95th	2600 g / 6th	3200 g / 33th	3100 g / 75th	3110 g / 50th
Birth HC / centile	unknown	unknown	unknown	unknown	unknown	39.5cm / > 97th	unknown	unknown	34.8 cm / 90th	34.5 cm / 75th
Neurodevelopment										
OFC	-2.5 SD	N/A	-0.3 SD	10th centile	-2.2 SD	-0.7 SD	-3.7 SD	26th centile	+3.9 SD hydrocephaly	+1.8 SD
Delayed development	+	+	+	+	+	+	+	+	+	+
Hypotonia	+	+	+	+	+	+	+	+	+	+
ID	+	+	+	+	+	+	+	+	N/A	+
Degree	severe	severe	severe	severe	severe	N/A	severe	severe	N/A	N/A
Absent speech	+	+	+	-	+	-	+	+	-	-
Sitting	3.5 y	1.5 y	-	-	20 m	11 m	12 m	18 m	N/A	N/A
Walking	7 y	4 y	-	-	-	3 y	5.5 y	5 y (in progress)	N/A	N/A
Toilet trained	-	-	-	-	-	-	-	-	N/A	N/A
Swallowing difficulties	+	-	+	-	+	+	+	+	-	-
ASD	-	-	-	-	-	+	-	-	N/A	-
Behavioral problems	aggressiveness	-	N/A	Sensory processing disorder	aggressiveness	aggressiveness	aggressiveness	impulse control	N/A	-
Abnormal movements	stereotypic	-	Choreatic	-	athetoid and stereotypic	arm extension	-	involuntary movements	N/A	-

Ataxia	N/A	-	-	+	+	+/- (wide gait)	-	NA	N/A	-
Strabismus	+	-	+	-	+	-	+	+	N/A	-
Seizures	-	-	+	-	-	+/- abnormal movements treated with levetiracetam / normal EEG	+	-	-	-
			generalized tonic-clonic				focal seizures			
Brain imaging										
Corpus callosum agenesis	+	+	+	+	+	+	+	+	-	-
Hippocampal dysplasia	+	+	N/A		N/A	N/A	-	N/A	N/A	N/A
Cerebellar hypoplasia	+	+/-	+	+	+	N/A	-	+	+	+
Hydrocephaly	-	-	-	-	-	N/A	-	-	+	-
Other						abnormal myelination	DW, encephalocele with intracranial hyper-tension			
Other features										
Short stature	-	-	-	-	+	-	+	+	+	+
Scoliosis	+	-	+	+	+	-	+	-	-	+
Other orthopedic problems	feet malposition, limited extension of the knees	-	premature closure of anterior fontanel	hip dysplasia requiring surgery	hip dislocation	hypermobility joints	declination of the body to the left side	-	11 pairs of ribs, foramina parietalia, large fontanelles	foramina parietalia, large fontanelles
Heart defect	-	-	-	-	-	-	-	-	atrio-ventricular canal	ASD and cleft of the mitral valve
Abnormal genitalia	micropenis	-	micropenis, cryptorchidism	not examined	-	-	-	-	slightly gaping vulva	slightly gaping vulva
Dysmorphic features	brachycephaly, deep-set eyes, short philtrum, full lips, macrostomia, ulnar deviation of the hands, narrow hands	-	prominent eyes and upper lip, large ears	deep set eyes, hypotelorism, high, narrow palate	plagiocephaly, hypotelorism, deep set eyes, high, narrow palate, tapering fingers	curly hair, hypertelorism, downslanting palpebral fissures, broad nasal root	not specific		ocular hypertelorism, downslanting palpebral fissures, depressed nasal bridge, apparently low- set ears, narrow palate	ocular hypertelorism, downslanting palpebral fissures, depressed nasal bridge, apparently low- set ears, narrow palate

Abbreviations: M, Male; F, Female; N/A, Not Available; htz, heterozygous; y, years-old; m, month; SD, Standard Deviation; ID, intellectual disability; HC, Head Circumference; OFC, Occipitofrontal circumference; DW, Dandy-Walker malformation; ASD, Autism Spectrum Disorder

Table 2. *In silico* pathogenicity prediction scores of p.(Glu41Lys) and p.(Gly47Arg) variants

		<i>DPYSL5</i> variant 1	<i>DPYSL5</i> variant 2
Mutation data	Mutation type	Missense	Missense
	Nucleotide change	c.121G>A	c.139G>A
	Predicted amino acid change	p.(Glu41Lys)	p.(Gly47Arg)
	Exon	2	2
<i>In silico</i> predictions	SIFT	Deleterious (score 0.02)	Deleterious (score 0.02)
	Mutation Taster	Disease causing (p-value: 1)	Disease causing (p-value: 1)
	Polyphen-2 (Hum-Div)	Benign (score 0.012)	Probably damaging (score 1)
	CADD_phred	24.5	27.9

Figure 1


Figure 1

A

p.Glu41Lys



Individual 1 (Tours)




Individual 2 (Amsterdam)




Individual 3 (Rotterdam)


B



c.139G>A, p.(Glu41Lys)



C



D




Figure 2





Figure 3



[Click here to access/download](#)

Supplemental Text and Figures

DPYSL5 Supplemental information ACCEPTED

30mar21.pdf